You're probably wondering why you've never heard about Prader-Willi syndrome before. There is a simple reason for it, and ...

Patients with PWS admitted to the hospital with COVID-19 showed increased risk of in-hospital mortality, severe disease, and mechanical ventilation.

First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno ...

Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome.

Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi syndrome. Soleno Therapeutics announced the medication will be available beginning in April.

on March 26 to treat hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), is now commercially available in the U.S. Soleno has established a comprehensive support ...

Though the exact mechanism of action is unclear, it is believed that in patients with Prader-Willi syndrome, diazoxide choline reduces hyperphagia through activation of the adenosine triphosphate ...

Gene variations in some people with autism strengthen the evidence for a genetic component. Among the genetic disorders ...

Aardvark Therapeutics, Inc.’s AARD share price has dipped by 8.26%, which has investors questioning if this is right time to buy.

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi ...